Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBI-TER 2 by Taylor, Allen J et al.
Vascular Health and Risk Management 2007:3(1) 159–164
© 2007 Dove Medical Press Limited. All rights reserved
159
O R I G I N A L   R E S E A R C H
Relationship between glycemic status  
and progression of carotid intima-media thickness 
during treatment with combined statin  
and extended-release niacin in ARBITER 2
Allen J Taylor 
Daming Zhu 
Lance E Sullenberger 
Hyun J Lee 
Jeannie K Lee 
Karen A Grace
Cardiology Service, Walter Reed Army 
Medical Center, Washington, DC, USA
Correspondence: Allen J Taylor 
Division Chief, Cardiology, Director, 
Cardiovascular Research, Walter Reed 
Army Medical Center, 6900 Georgia 
Avenue, NW, Building 2, Room 4A34, 
Washington, DC 20307-5001, USA 
Tel +1 202 782 2887 
Fax +1 202 782 3238 
Email allen.taylor@na.amedd.army.mil 
A
U
T
H
O
R
 
C
O
P
Y
.
N
o
t
 
f
o
r
 
p
u
b
l
i
c
a
t
i
o
n
Background: We previously reported in a placebo-controlled study that extended-release 
niacin slowed the progression of carotid atherosclerosis when added to statin monotherapy. 
This analysis examines the relationship between glycemic status and the effects of niacin on 
common carotid intima-media thickness (CIMT) and HDL cholesterol.
Methods: Post-hoc, subgroup analysis of ARBITER 2, a randomized, placebo-controlled trial 
of once-daily extended-release niacin (1000 mg) added to background statin therapy in 167 
patients (mean age 67 years) with known coronary heart disease. The primary analysis was 
a comparison of the primary endpoint, the change in CIMT, between participants with either 
normal glycemic status, diabetes mellitus (DM) or the metabolic syndrome (MS).
Results: Baseline cardiovascular risk variables were signiﬁcantly worse in those with abnormal 
glycemic status, particularly among subjects with MS. Niacin increased HDL-C to a similar 
degree (~20%) across normals, DM and MS. Placebo-treated patients had the greatest CIMT 
progression, regardless of glycemic status. The lowest progression rate was observed in niacin 
treated patients with normal glycemic status. Among all niacin treated subjects, there was a 
signiﬁcant linear relationship between change in CIMT and change in HDL-C (r = –0.16; 
p = 0.05), which was of similar magnitude in subgroups with normal glycemic status (r = 
–0.23; p = 0.08) and DM (r = –0.22; p = 0.17). In those with MS, there was no relationship 
between changes in HDL and CIMT, (r = 0.11; p = 0.44), whereas blood glucose was positive 
correlated to change in CIMT (r = 0.30; p = 0.04). In multivariable linear models controlling 
for MS characteristics and blood glucose changes, only the change in HDL independently 
predicted change in CIMT.
Conclusions: During niacin treatment, increases in HDL-C are related to changes in CIMT in 
the setting of both normal glycemic status and diabetes mellitus.
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Introduction
Atherogenic dyslipidemia, deﬁned as low HDL-C, elevated triglycerides (TG), and 
increased levels of small-dense LDL-C contributes to the development of atheroscle-
rosis and the risk of developing CHD among individuals with the metabolic syndrome 
(MS) and diabetes mellitus (DM) (Savage et al 2005). Thus the effect of niacin, 
which can favorably impact atherogenic dyslipidemia including increasing HDL-C 
concentrations by 20% or more (Guyton et al 1998), is of particular interest among 
these patient subgroups. ARBITER 2 was a double-blind, placebo controlled study 
of extended-release niacin (ERN; Niaspan® 1000 mg/d) on 12-month progression of 
carotid intima-media thickness (CIMT) among patients with known coronary heart 
disease, good control of their LDL-C during statin monotherapy, but moderately low 
HDL-C (Taylor et al 2004). The study found signiﬁcant progression of carotid artery Vascular Health and Risk Management 2007:3(1) 160
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intima-media thickness (CIMT) among all placebo treated 
patients, whereas ERN resulted in a 21% increase in HDL-C 
and stabilized CIMT.
In the original report from ARBITER 2, a post 
hoc analysis suggested a possible attenuation of the athero-
sclerosis stabilization response to ERN among subjects with 
DM or MS. In this report, we explore this relationship further, 
speciﬁcally analyzing the relationships to CIMT progression 
within these subgroups and the relationship between the 
changes in CIMT and HDL-C.
Methods
Study population
This trial was a single center study conducted at Walter Reed 
Army Medical Center, a university-afﬁliated, suburban, 
tertiary care military medical center. The institution’s 
Department of Clinical Investigation approved the study. 
Volunteer research subjects were recruited from the cardiol-
ogy and general medicine services. The study included male 
and female patients, greater than 30 years old, with known 
coronary vascular disease. All subjects were required to be 
currently treated with a statin drug with documented LDL 
cholesterol below 130 mg/dL and HDL cholesterol below 45 
mg/dL. Those with known intolerance to niacin, history of 
liver disease (cirrhosis, chronic hepatitis) or abnormal liver 
associated enzymes (>3 × the upper laboratory reference 
value) were excluded.
Randomization
After providing informed consent, subjects were random-
ized (allocation concealed) in a 1:1 fashion to either receive 
either extended release niacin (Niaspan) or matching placebo 
provided by Kos Pharmaceuticals, Inc. (Weston, FL, USA). 
Further details of the randomization procedures are as pub-
lished (Taylor et al 2004). Study medication was initiated 
at a daily dose of 500 mg for 30 days, and then increased 
to 1000 mg for the duration of the 12-month study period. 
Study medication was taken at night with a recommenda-
tion it be co-administered with their usual daily dose of 
aspirin. All patients taking either vitamin C or vitamin E 
were strongly encouraged to discontinue their use of these 
supplements during the study to avoid possible interference 
with the response to niacin (Cheung et al 2001). Between 
December 2001 and May 2003, 167 patients were enrolled 
in the trial and the ﬁnal follow-up was completed in May 
2004. Patients were individually unblinded to their study 
medication assignment after completion of their 12-month 
endpoint assessment. The predeﬁned primary endpoint of this 
study was the change in mean common carotid intima-media 
thickness after 1 year assessed within each study medication 
group using a paired t-test.
Cardiovascular medications and hypoglycemic medica-
tions were recorded from the patient history and the electronic 
medical record. Serial measurements of lipid concentrations, 
fasting blood glucose, and liver associated enzymes were 
performed. High-frequency ultrasound measurements of 
the common carotid artery intima-media thickness were 
performed at baseline and after 12 months. Further details 
of the analysis of CIMT and laboratory parameters are as 
previously reported (Taylor et al 2004).
The present analysis
The present analysis explores the relationship between the 
baseline presence of DM or MS, the assigned study drug 
(placebo and niacin) and the observed changes in CIMT (the 
primary endpoint of ARBITER 2). Diabetes mellitus and 
MS were determined using measurements from the baseline 
characteristics including historical variables, medications, 
and measured laboratory values. We deﬁned DM using a 
composite deﬁnition including patient history, the use of 
hypoglycemic medications, or a fasting blood glucose ≥126 
mg/dL. Among participants without DM, the MS was deﬁned 
according to the criteria of the National Cholesterol Educa-
tion Program Adult Treatment Panel III guidelines using the 
baseline clinical and laboratory assessment (NCEP Writing 
Group 2001). This assessment occurred while the patients 
were taking their prescribed medications that included statin 
medications in all patients, and could also include anti- 
hypertensive medications or hypoglycemic agents.
Statistical analysis
This was a non-prespeciﬁed post-hoc subgroup analysis. 
Comparisons between patient categories (normal glycemic 
status, MS, and DM) were performed using Chi-square or 
ANOVA as appropriate. Bivariate correlations between the 
change in HDL-C and change in CIMT observed during trial 
were sought. We performed multivariable linear regression 
using the change in CIMT as the independent variable. 
Dependent variables including gender, metabolic syndrome 
variables and the change in HDL-C were entered into the 
model using both forward and backward entry. Models were 
tested for inﬂuential data points using leverage and colin-
earity diagnostics. The results of the model are reported as 
r values (partial correlations). All statistical analyses were Vascular Health and Risk Management 2007:3(1) 161
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performed using SPSS software (version 13.0, SPSS Inc., 
Chicago, IL, USA). Values are reported as mean ± standard 
deviation, except where indicated. A 2-sided P value of ≤0.05 
was considered statistically signiﬁcant.
Results
The mean patient age was 67 ± 10 years and 91% were 
men. Known coronary heart disease was present in all 167 
patients, with a prior history of myocardial infarction reported 
in 83 (49.7%), percutaneous coronary revascularization in 
77 (46.1%), coronary bypass surgery in 68 (40.7%). Mean 
baseline lipid concentration included a total cholesterol 
157 ± 27 mg/dL, LDL-C 89 ± 20 mg/dL, HDL-C 40 ±   
7 mg/dL and triglycerides 161 ± 91 mg/dL. All patients 
were receiving statin drugs upon entry to the study with a 
mean duration of treatment of 4.8 ± 4.3 years. Most patients 
(n = 156, 93.4%) were being treated with simvastatin, and the 
majority (n = 160, 95.8%) were receiving a daily dose of 20 
mg or above. All patients had non-insulin dependent diabetes 
mellitus. The proportion of subjects prescribed hypoglycemic 
medications including insulin, metformin, and sulfonylureas 
was similar in the niacin and placebo groups.
There were signiﬁcant differences among baseline cardio-
vascular risk variables among patients with normal glycemic 
status, DM, and MS (Table 1). Past history and medications 
were generally similar in these groups, although those with 
DM were more commonly treated with angiotensin converting 
enzyme inhibitors. However, among measured cardiovascular 
risk variables, participants with metabolic syndrome had 
signiﬁcantly higher blood pressure, triglycerides, BMI, and 
signiﬁcantly lower HDL-C, compared with those with normal 
glycemic status and, for some variables, even those with DM 
(Table 2). Although this was in part related to the application 
of the deﬁnition of metabolic syndrome, it is notable that, in 
these individuals, metabolic syndrome was persistent, despite 
the frequent use of medications (eg, anti-hypertensive medica-
tions) to treat the metabolic syndrome components.
During treatment with the study drug, hypoglycemic 
medications were added to 2 subjects in the placebo group 
(one each, metformin, and sulfonylurea) versus 3 in the 
niacin group (insulin, n = 2; metformin n = 1). There was no 
signiﬁcant difference between the placebo and ERN groups 
with respect to the change in fasting blood glucose values 
among subjects with either normal glycemic status, MS, or 
DM. Among either placebo or ERN treated subjects, similar 
changes in HDL-C were observed in all 3 groups (Table 3). 
Signiﬁcant progression of CIMT was observed in all 3 
placebo treated groups. In comparison, none of the ERN 
treated groups had signiﬁcant CIMT progression. However, 
the difference in the change in CIMT between the placebo 
and ERN groups, although directionally similar, tended to be 
of lower magnitude in patients with DM or MS. In normal 
glycemic status, CIMT progression compared with placebo 
was reduced by 109% (p < 0.05), vs. 33% in metabolic syn-
drome and 53% in DM (p = NS for both comparisons with 
placebo) (Table 3 and Figure 1).
Table 1 Baseline characteristics of 167 patients randomly assigned to either placebo or extended-release niacin
    Placebo n = 80  Niacin n = 87  P
Male gender  74 (92.5)  78 (89.7)  0.52
Age, mean ± SD  68 ± 10  67 ± 10  0.64
Diabetes mellitus (n, %)  22 (27.5)  24 (27.6)  0.99
Hypertension (n, %)  61 (76.3)  64 (73.6)  0.69
Tobacco use (n, %)  5 (6.3)  12 (13.8)  0.23
Family history of coronary heart disease (n, %)  39 (48.8)  33 (37.9)  0.16
Metabolic syndrome  42 (52.5)  43 (49.4)  0.69
History of coronary heart disease
  Myocardial infarction  42 (52.5)  41 (47.1)  0.49
  Percutaneous coronary revascularization  35 (43.8)  42 (48.8)  0.51
  Coronary bypass surgery  28 (35.0)  40 (46.0)  0.15
  Angina with documented ischemia  27 (33.8)  26 (29.9)  0.59
Medications
  Beta blocker  63 (78.8)  69 (79.3)  0.93
  Aspirin  68 (85.0)  75 (86.2)  0.82
  Angiotensin converting enzyme inhibitor  42 (57.5)  54 (62.1)  0.21
  Insulin  8 (10)  9 (10.3)  0.94
  Metformin  10 (12.5)  10 (11.5)  0.84
  Sulfonylurea  9 (11.4)  8 (9.2)  0.64Vascular Health and Risk Management 2007:3(1) 162
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On univariate analysis, there was a statistically signiﬁcant 
inverse correlation between change in CIMT and change in 
HDL (r = –0.16; p = 0.05) which was of similar magnitude 
in the subgroups with normal glycemic status (r = –0.23;   
p = 0.08) and DM (r = –0.22; p = 0.17). No relationship be-
tween change in HDL-C and CIMT was observed in the MS 
subgroup (r = 0.11; p = 0.44). In multivariate models control-
ling for the DM or MS, and for the individual components of 
the metabolic syndrome, gender and change in HDL-C, only 
change in HDL-C was related (inversely) to change in CIMT 
(Table 3). In the subgroup of participants with MS, blood 
glucose level was positively correlated to change in CIMT 
(r = 0.30; p = 0.04). Controlling for the change in HDL-C, 
changes in BG were unrelated to the CIMT effects.
Discussion
ARBITER-2 was the ﬁrst study to demonstrate the impact 
of combination therapy with statin and extended release 
niacin for the endpoint of CIMT in the setting of moderate 
increases in HDL-C (Taylor et al 2004). However, a blunting 
of the effect of ERN on CIMT appeared to be present in the 
subgroup of participants with either DM or MS, leading to 
concerns regarding therapeutic efﬁcacy in this important sub-
group. The present analysis shows the relationships between 
changes in HDL-C and CIMT were similar in those with 
either DM or normal glycemic status. However, among 
participants with persistent metabolic syndrome (deﬁned as 
metabolic syndrome despite the use of medications to treat its 
components) in whom other cardiovascular risk factors were 
poorly controlled, the impact of raising HDL-C on CIMT 
appears to be blunted. This reinforces the multi-factorial 
nature of cardiovascular risk, for which the global control 
lipid and non-lipid risk factors is crucial.
Plasma levels of HDL-C, with its major apolipoprotein 
(apo) component apoA-I, are inversely associated with 
coronary heart disease (CHD) risk (Gordon et al 1989). As 
an emerging therapeutic target for primary prevention and 
secondary prevention of coronary heart disease, raising 
HDL-C is gaining increasing attention in recognition that 
the protection afforded by decreasing LDL-C, even to very 
low values, is incomplete (Cannon et al 2004; de Lemos et al 
2004). A key function of HDL is its pivotal role in reverse 
cholesterol transport (RCT) (Zhang et al 2003), a dynamic 
process leading to the stabilization or regression of athero-
sclerotic plaque. Recent clinical evidence supporting this 
include the results of TromsØ study showed that elevated 
HDL levels were protective against plaque progression 
in right carotid artery (Johnsen et al 2005). In this study, 
transformation of the plaque mass into higher echogenicity 
was associated with reduced plaque growth. This ﬁnding is 
plausible because removal of lipids by HDL may decrease 
the echolucent proportion of the plaque and therefore make 
the regressed plaque more echogenic (ﬁbrous) (Gronholdt 
et al 1998). In addition to the plasma level of HDL, the size 
Table 2 Measured baseline cardiovascular risk variables in subjects with normal glycemic status, metabolic syndrome, or diabetes 
mellitus
  Normal  Metabolic syndrome  Diabetes mellitus  ANOVA P
N  70  51  46 
LDL-C  91 ± 21  85 ± 15  89 ± 24  NS
HDL-C  43 ± 6  35 ± 4  40 ± 7  <0.001
TG  131 ± 62  181 ± 99  188 ± 104  0.001
Blood glucose  96 ± 12  101 ± 11  130 ± 44  <0.001
Systolic BP (mmHg)  127 ± 19  141 ± 20  135 ± 23  0.001
Diastolic BP (mmHg)  73 ± 12  78 ± 12  71 ± 14  0.012
Body Mass Index  27.8 ± 5.7  30.8 ± 5.3  30.6 ± 6.2  0.005
Waist girth (cm)  104 ± 15  112 ± 8  113 ± 16  0.001
Table 3 Changes in HDL and carotid intima-media thickness with placebo or extended-release niacin among subgroups according to 
glycemic status
  Normal    Metabolic syndrome  Diabetes mellitus
Study drug  Placebo  ERN  Placebo  ERN  Placebo  ERN
n  31  30  21  26  19  22
DHDL (mg/dL ± SD)  –1.1 ± 5.0  6.8 ± 12.2  1.6 ± 5.2  6.3 ± 5.6  –0.6 ± 3.0  6.4 ± 6.0
DCIMT (mm ± SEM)  0.044 ± .024  –0.004 ± .021  0.046 ± 0.012  0.031 ± 0.018  0.043 ± 0.017  0.020 ± 0.023Vascular Health and Risk Management 2007:3(1) 163
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and chemical composition of HDL affects its protective effect 
against atherosclerosis. In a HATS substudy, Schaefer and 
colleagues showed that treatment with niacin and simvastatin 
signiﬁcantly increased the two large apoA-I-containing HDL 
subpopulations, α1 and pre α1. A signiﬁcant inverse correla-
tion (r = –0.235, p < 0.01) was noted between the changes 
in α1 HDL particle concentration and coronary artery 
stenosis progression (Asztalos et al 2003). In concordance 
with these observations, ARBITER 2 demonstrated for the 
ﬁrst time an incremental independent effect of combination 
therapy with niacin and simvastatin to retard the progres-
sion of atherosclerosis in comparison to statin monotherapy. 
A signiﬁcant, independent inverse correlation was found   
between the change in HDL-C and change in CIMT, 
which was notably of similar magnitude to that observed 
by Schaefer and colleagues.
Most patients with diabetes mellitus or metabolic syndrome 
have complex lipid disorders characterized by low HDL-C, 
high TG, high LDL-C, and small, dense LDL-C particles 
(Jacobs et al 2005). Combination therapy with niacin and a 
statin is an appropriate option for treating the cluster of lipid 
abnormalities in these patients because of their synergistic 
effect in increasing HDL-C, decreasing TG and LDL-C, and 
increasing LDL-particle size. In our study, similar changes in 
HDL-C were achieved in subgroups of normal glycemic status, 
DM and MS with combination therapy of niacin-simvastatin, 
suggesting the HDL-modulating effect of the combination 
therapy regimen was clinically equivalent in these three sub-
groups. However, although with similar directional trends, 
the smaller relative effect in retarding CIMT progression in 
DM and MS subgroups may be due to other poorly controlled 
cardiovascular risk factors, particularly in the subgroup with 
MS. The non-parallel effect between modulating HDL and 
retarding CIMT progression in these subgroups was further 
conﬁrmed by correlation analysis. Although a similar mag-
nitude of inverse correlation was observed between change 
in CIMT and change in HDL in the subgroups with normal 
glycemic status and DM, no relationship was observed in the 
MS subgroup. Differences among non-lipid factors between 
these subgroups and their interactions are likely critical, as 
shown by the positive correlation between blood glucose level 
and change in CIMT in MS subgroup.
Our results highlight the need to broadly identify and 
treat cardiovascular risk, including control of all lipid and 
Figure 1 Carotid intima-media thickness (CIMT) change across 12 months in placebo and extended-release niacin treated patients in subjects with normal glycemic status, 
metabolic syndrome or diabetes mellitus. 
Abbreviations: DM, diabetes mellitus; MS, metabolic syndrome; NS, nonsigniﬁcant.
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non-lipid risk factors, concurrent with efforts to increase 
HDL-C. The present analysis was a non-prespeciﬁed sub-
group analysis involving small subgroups, and thus requires 
cautious interpretation and is best regarded as hypothesis 
generating and requiring further study in dedicated clinical 
trials. Speciﬁcally, the original trial design was not powered 
to detect treatment-related differences on CIMT in either the 
DM or MS subgroups. Although the worse risk factor status 
among participants with the metabolic syndrome is in part 
based upon the application of the NCEP ATPIII deﬁnition, 
the individuals with persistent metabolic syndrome on phar-
macotherapy for blood pressure and lipids distinguishes them 
as a higher risk subgroup and is a potential source of bias 
towards individuals with more severe metabolic syndrome. 
Thus, the results may not apply to individuals with de novo 
metabolic syndrome diagnosed off pharmacotherapy.
In conclusion, during niacin treatment, increases in 
HDL-C are related to changes in CIMT. Because the pres-
ence of other poorly controlled cardiovascular risk factors 
may blunt this effect, concurrent control of lipid and non-
lipid risk factors is indicated. In particular, individualization 
of treatment plans based on risk stratiﬁcation paradigms 
should be emphasized for dyslipidemic patients, especially 
patients with diabetes mellitus or metabolic syndrome. Large 
scale clinical trials focused on pre-speciﬁcation of patient 
subgroups are warranted to determine the effect of niacin 
and other lipid-modulating agents on CIMT progression in 
patients with diabetes mellitus or metabolic syndrome.
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